Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage ib1-iib cervical cancer patients with intermediate-risk or high-risk factors; A 13-year experience

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 567-575

  Okazawa, Mika ^a   Mabuchi, Seiji ^b   Isohashi, Fumiaki ^c   Suzuki, Osamu ^a   Yoshioka, Yasuo ^c   Sasano, Tomoyuki ^b   Ohta, Yukinobu ^a   Kamiura, Shoji ^a   Ogawa, Kazuhiko ^c   Kimura, Tadashi ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Concurrent chemoradiotherapy; Radical hysterectomy; Survival

Indexed keywords

NEDAPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADICAL HYSTERECTOMY; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PELVIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84876224242     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828703fd     Document Type: Article

References (30)

1. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535-540.
2. Perez CA, Camel HM, Kao MS, et al. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: Final report. Gynecol Oncol. 1987;27:129-140.
3. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83(suppl 1):41-78.
4. Mabuchi S, Okazawa M, Isohashi F, et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecol Oncol. 2011;123:241-247.
5. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352-357.
6. Samlal RA, van der Velden J, Schilthuis MS, et al. Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma. Gynecol Oncol. 1997;64:463-467.
7. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
8. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: Follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169-176.
9. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177-183.
10. Kim K, Kang SB, Chung HH, et al. Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors. Eur J Surg Oncol. 2009;35:192-196.
11. Ryu SY, Park SI, Nam BH, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79:794-799.
12. Song S, Song C, Kim HJ, et al. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: Impact of treatment period and concurrent chemotherapy. Gynecol Oncol. 2012;124:63-67.
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Cervical Cancer-version 2.2013. Available at: Http://www.nccn.org/ professionals/physician-gls/pdf/cervical.pdf. Accessed December 3, 2012.
14. Mabuchi S, Morishige K, Isohashi F, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol. 2009;115:482-487.
15. Mabuchi S, Okazawa M, Isohashi F, et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecol Oncol. 2011;120:94-100.
16. Mabuchi S, Okazawa M, Matsuo K, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: Adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127:114-120.
17. Okazawa M, Mabuchi S, Isohashi F, et al. The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy. Int J Gynecol Cancer. 2012;22:490-497.
18. Monk BJ, Alberts DS, Burger RA, et al. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol Oncol. 1998;71:308-312.
19. Mabuchi S, Ugaki H, Isohashi F, et al. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: A comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest. 2010;69:224-232.
20. Mabuchi S, Kimura T. Nedaplatin: A radiosensitizing agent for patients with cervical cancer. Chemother Res Pract. 2011;2011:963159.
21. Mabuchi S, Isohashi F, Yoshioka Y, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010;20:834-840.
22. Mabuchi S, Isohashi F, Maruoka S, et al. Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet. 2012;286:179-185.
23. NCT00980954. National Cancer Institute. Available at: Http://www.cancer.gov/clinicaltrials/search/view?cdrid=654709& version=HealthProfessional&protocolsearchid=10780359. Accessed August 22, 2012.
24. NCT01101451. National Cancer Institute. Available at: Http://www.cancer.gov/clinicaltrials/search/view?cdrid= 670125&version= HealthProfessional& protocolsearchid=10780359. Accessed August 22, 2012.
25. Undurraga M, Loubeyre P, Dubuisson JB, et al. Early-stage cervical cancer: Is surgery better than radiotherapy? Expert Rev Anticancer Ther. 2010;10:451-460.
26. Yamashita H, Okuma K, Kawana K, et al. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: A retrospective study. Am J Clin Oncol. 2010;33:583-586.
27. Huscher A, Bignardi M, Magri E, et al. Determinants of small bowel toxicity in postoperative pelvic irradiation for gynaecological malignancies. Anticancer Res. 2009;29:4821-4826.
28. Hasselle MD, Rose BS, Kochanski JD, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2011;80:1436-1445.
29. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: Comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438-1444.
30. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354-1360.